Thoracal Radiotherapy and Tarceva (ThoRaT)

University of Oslo (UIO)

Status and phase: Terminated; Phase 2

Conditions: Cancer

Treatments: Radiation: Radiation; Drug: Erlotinib

Study type: Interventional

Funder types: Other

Identifiers

NCT02714530

ThoRaT

Details and patient eligibility

About

The purpose of this study is to determine if erlotinib given orally along with concurrent palliative irradiation to lung cancer improves local control compared to those treated with radiotherapy alone.

Full description

Endpoints:

Primary:

• To determine if erlotinib given orally along with concurrent external beam radiation therapy, prolongs local tumour control as determined by CT evaluation compared to treatment with external beam radiation therapy alone

Secondary:

• To confirm the safety profile of erlotinib along with concurrent external beam radiation therapy.
• To evaluate if erlotinib along with concurrent external beam radiation therapy, improve quality of life as assessed with the EORTC QLQ-C30 and the EORTC QLQ-LC13.
• To evaluate if PET-CT examination can be used to predict response to treatment.
• To evaluate overall survival in the different groups

Trial Design: Open multicenter two-armed randomized phase II trial.

Enrollment: 118 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >18 years
• Histological or cytological verified NSCLC
• Palliative radiotherapy to thorax indicated
• ECOG Performance status 0-2
• Fertile patients must use contraception
• Signed informed consent
• Ability to understand and fill in QoL questionnaires
• Capability to take per os medication
• Serum bilirubin < 2 times upper limit of normal (ULN)
• AST and ALT < 2 times ULN (< 5 times ULN if liver metastases are present)
• Creatinine < 5 times ULN

Exclusion criteria

• Pregnancy or nursing
• Other prior or concurrent malignant disease likely to interfere with study treatment or comparisons
• No evidence of other significant laboratory finding or concurrent uncontrolled medical illness, that in the opinion of the investigator, would interfere with study treatment or results comparison or render the patient at high risk for treatment complications
• No prior radiotherapy to the same organ / place
• No concurrent treatment with other experimental drugs
• Known brain metastases in need of radiotherapy
• Known hypersensitivity to erlotinib or other substances in the erlotinib tablets.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

118 participants in 2 patient groups

Radiotherapy combined with erlotinib

Experimental group

Description:

Standard treatment 3 Gy x 10 to lung tumor and mediastinal lymph nodes and erlotinib given concomitantly, 150 mg p.o. daily from the day before radiation, until the last day of radiation.

Treatment:

Radiation: Radiation

Drug: Erlotinib

Radiotherapy alone

Active Comparator group

Description:

Radiotherapy 3 Gy x 10 alone

Treatment:

Radiation: Radiation